View ValuationMagis 향후 성장Future 기준 점검 3/6Magis (는) 각각 연간 20.3% 및 4.2% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 17.9% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 12.1% 로 예상됩니다.핵심 정보20.3%이익 성장률17.90%EPS 성장률Chemicals 이익 성장20.8%매출 성장률4.2%향후 자기자본이익률12.06%애널리스트 커버리지Low마지막 업데이트04 May 2026최근 향후 성장 업데이트Major Estimate Revision • Oct 12Consensus EPS estimates fall by 28%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from €79.6m to €76.1m. EPS estimate also fell from €0.766 per share to €0.551 per share. Net income forecast to shrink 42% next year vs 17% decline forecast for Chemicals industry in Italy. Consensus price target down from €14.50 to €12.75. Share price fell 2.8% to €10.30 over the past week.Price Target Changed • Oct 10Price target decreased by 15% to €12.75Down from €15.00, the current price target is an average from 2 analysts. New target price is 24% above last closing price of €10.30. Stock is down 21% over the past year. The company is forecast to post earnings per share of €1.63 for next year compared to €1.54 last year.Major Estimate Revision • Aug 05Consensus EPS estimates fall by 39%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from €86.0m to €81.2m. EPS estimate also fell from €1.59 per share to €0.967 per share. Net income forecast to shrink 37% next year vs 6.0% decline forecast for Chemicals industry in Italy. Consensus price target down from €18.25 to €15.00. Share price fell 16% to €11.60 over the past week.모든 업데이트 보기Recent updates분석 기사 • Apr 22Magis' (BIT:MGS) Weak Earnings May Only Reveal A Part Of The Whole PictureThe subdued market reaction suggests that Magis S.p.A.'s ( BIT:MGS ) recent earnings didn't contain any surprises. We...New Risk • Apr 21New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.1% Last year net profit margin: 11% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 92% Paying a dividend despite having no free cash flows. Minor Risks Profit margins are more than 30% lower than last year (4.1% net profit margin). Shareholders have been diluted in the past year (15% increase in shares outstanding). Market cap is less than US$100m (€57.0m market cap, or US$67.0m).New Risk • Apr 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (21% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Shareholders have been diluted in the past year (15% increase in shares outstanding). Market cap is less than US$100m (€56.7m market cap, or US$66.9m).공지 • Apr 14Magis S.p.A., Annual General Meeting, Apr 28, 2026Magis S.p.A., Annual General Meeting, Apr 28, 2026, at 09:30 W. Europe Standard Time.New Risk • Feb 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (5.2% average weekly change). Shareholders have been diluted in the past year (15% increase in shares outstanding). Market cap is less than US$100m (€56.4m market cap, or US$67.1m).New Risk • Dec 30New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Shareholders have been diluted in the past year (15% increase in shares outstanding). Market cap is less than US$100m (€52.7m market cap, or US$61.9m).공지 • Oct 24Magis S.p.A. (BIT:MGS) announces an Equity Buyback for €0.8 million worth of its shares.Magis S.p.A. (BIT:MGS) announces an share repurchase program. Under the program, the company will repurchases up to €0.8 million. The program will valid till 18 months.분석 기사 • Oct 16Why The 24% Return On Capital At Magis (BIT:MGS) Should Have Your AttentionIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. One common...Major Estimate Revision • Oct 12Consensus EPS estimates fall by 28%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from €79.6m to €76.1m. EPS estimate also fell from €0.766 per share to €0.551 per share. Net income forecast to shrink 42% next year vs 17% decline forecast for Chemicals industry in Italy. Consensus price target down from €14.50 to €12.75. Share price fell 2.8% to €10.30 over the past week.Price Target Changed • Oct 10Price target decreased by 15% to €12.75Down from €15.00, the current price target is an average from 2 analysts. New target price is 24% above last closing price of €10.30. Stock is down 21% over the past year. The company is forecast to post earnings per share of €1.63 for next year compared to €1.54 last year.New Risk • Oct 01New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2024 fiscal period end). Earnings are forecast to decline by an average of 2.0% per year for the foreseeable future. Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (€62.3m market cap, or US$73.0m).New Risk • Sep 29New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 2.5% per year for the foreseeable future. Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (€66.3m market cap, or US$77.6m).Buy Or Sell Opportunity • Sep 24Now 20% overvaluedOver the last 90 days, the stock has fallen 16% to €11.40. The fair value is estimated to be €9.49, however this is not to be taken as a sell recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 1.5% per annum. Earnings are forecast to decline by 2.5% per annum over the same time period.Buy Or Sell Opportunity • Sep 01Now 20% overvaluedOver the last 90 days, the stock has fallen 15% to €11.50. The fair value is estimated to be €9.56, however this is not to be taken as a sell recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 1.5% per annum. Earnings are forecast to decline by 2.5% per annum over the same time period.Buy Or Sell Opportunity • Aug 13Now 20% overvaluedOver the last 90 days, the stock has fallen 13% to €11.50. The fair value is estimated to be €9.58, however this is not to be taken as a sell recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 1.5% per annum. Earnings are forecast to decline by 2.5% per annum over the same time period.Major Estimate Revision • Aug 05Consensus EPS estimates fall by 39%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from €86.0m to €81.2m. EPS estimate also fell from €1.59 per share to €0.967 per share. Net income forecast to shrink 37% next year vs 6.0% decline forecast for Chemicals industry in Italy. Consensus price target down from €18.25 to €15.00. Share price fell 16% to €11.60 over the past week.New Risk • Aug 04New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 2.5% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 2.5% per year for the foreseeable future. Minor Risks Share price has been volatile over the past 3 months (5.6% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (€65.7m market cap, or US$76.1m).Valuation Update With 7 Day Price Move • Jul 31Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to €11.80, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 15x in the Chemicals industry in Italy. Negligible returns to shareholders over past year.New Risk • Jun 12New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (€78.7m market cap, or US$91.3m).New Risk • Jun 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Market cap is less than US$100m (€66.1m market cap, or US$75.3m).New Risk • Apr 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (€69.1m market cap, or US$78.4m).공지 • Apr 15Magis S.p.A., Annual General Meeting, Apr 28, 2025Magis S.p.A., Annual General Meeting, Apr 28, 2025, at 16:30 W. Europe Standard Time.Buy Or Sell Opportunity • Apr 04Now 24% overvalued after recent price riseOver the last 90 days, the stock has risen 9.9% to €13.30. The fair value is estimated to be €10.75, however this is not to be taken as a sell recommendation but rather should be used as a guide only.공지 • Apr 02Magis S.p.A. announces Annual dividend, payable on May 07, 2025Magis S.p.A. announced Annual dividend of EUR 0.9200 per share payable on May 07, 2025, ex-date on May 05, 2025 and record date on May 06, 2025.분석 기사 • Mar 22We Think Magis (BIT:MGS) Might Have The DNA Of A Multi-BaggerIf you're looking for a multi-bagger, there's a few things to keep an eye out for. Amongst other things, we'll want to...Buy Or Sell Opportunity • Mar 13Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 2.4% to €13.00. The fair value is estimated to be €10.57, however this is not to be taken as a sell recommendation but rather should be used as a guide only.분석 기사 • Oct 04Magis (BIT:MGS) Strong Profits May Be Masking Some Underlying IssuesMagis S.p.A.'s ( BIT:MGS ) robust recent earnings didn't do much to move the stock. We think this is due to investors...Reported Earnings • Sep 29First half 2024 earnings releasedFirst half 2024 results: Revenue: €43.8m (up 4.7% from 1H 2023). Net income: €4.52m (up 1.4% from 1H 2023). Profit margin: 10% (in line with 1H 2023). Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Chemicals industry in Italy.New Risk • Sep 27New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (8.9% increase in shares outstanding). Market cap is less than US$100m (€63.5m market cap, or US$70.9m).New Risk • Apr 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€51.5m market cap, or US$54.8m).Reported Earnings • Sep 25First half 2023 earnings releasedFirst half 2023 results: Net income: €4.46m (up €4.46m from 1H 2022).이익 및 매출 성장 예측BIT:MGS - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20288769N/A212/31/20278467N/A212/31/20268055N/A112/31/2025773-31N/A9/30/2025784-31N/A6/30/2025796-31N/A3/31/202580737N/A12/31/2024819914N/A9/30/2024828814N/A6/30/2024828713N/A3/31/2024818712N/A12/31/2023808710N/A9/30/2023828N/AN/AN/A6/30/20238371620N/A3/31/20238871317N/A12/31/2022938913N/A9/30/2022908N/AN/AN/A6/30/2022877-6-3N/A3/31/2022796-6-3N/A12/31/2021704-6-2N/A12/31/202053139N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: MGS 의 연간 예상 수익 증가율(20.3%)이 saving rate(3.3%)보다 높습니다.수익 vs 시장: MGS 의 연간 수익(20.3%)이 Italian 시장(10.6%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: MGS 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: MGS 의 수익(연간 4.2%)이 Italian 시장(연간 5.6%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: MGS 의 수익(연간 4.2%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: MGS의 자본 수익률은 3년 후 12.1%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YMaterials 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/08 07:00종가2026/05/08 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Magis S.p.A.는 2명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Andrea BonfaBanca Akros S.p.A. (ESN)Marco GrecoValueTrack
Major Estimate Revision • Oct 12Consensus EPS estimates fall by 28%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from €79.6m to €76.1m. EPS estimate also fell from €0.766 per share to €0.551 per share. Net income forecast to shrink 42% next year vs 17% decline forecast for Chemicals industry in Italy. Consensus price target down from €14.50 to €12.75. Share price fell 2.8% to €10.30 over the past week.
Price Target Changed • Oct 10Price target decreased by 15% to €12.75Down from €15.00, the current price target is an average from 2 analysts. New target price is 24% above last closing price of €10.30. Stock is down 21% over the past year. The company is forecast to post earnings per share of €1.63 for next year compared to €1.54 last year.
Major Estimate Revision • Aug 05Consensus EPS estimates fall by 39%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from €86.0m to €81.2m. EPS estimate also fell from €1.59 per share to €0.967 per share. Net income forecast to shrink 37% next year vs 6.0% decline forecast for Chemicals industry in Italy. Consensus price target down from €18.25 to €15.00. Share price fell 16% to €11.60 over the past week.
분석 기사 • Apr 22Magis' (BIT:MGS) Weak Earnings May Only Reveal A Part Of The Whole PictureThe subdued market reaction suggests that Magis S.p.A.'s ( BIT:MGS ) recent earnings didn't contain any surprises. We...
New Risk • Apr 21New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.1% Last year net profit margin: 11% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 92% Paying a dividend despite having no free cash flows. Minor Risks Profit margins are more than 30% lower than last year (4.1% net profit margin). Shareholders have been diluted in the past year (15% increase in shares outstanding). Market cap is less than US$100m (€57.0m market cap, or US$67.0m).
New Risk • Apr 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (21% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Shareholders have been diluted in the past year (15% increase in shares outstanding). Market cap is less than US$100m (€56.7m market cap, or US$66.9m).
공지 • Apr 14Magis S.p.A., Annual General Meeting, Apr 28, 2026Magis S.p.A., Annual General Meeting, Apr 28, 2026, at 09:30 W. Europe Standard Time.
New Risk • Feb 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (5.2% average weekly change). Shareholders have been diluted in the past year (15% increase in shares outstanding). Market cap is less than US$100m (€56.4m market cap, or US$67.1m).
New Risk • Dec 30New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Shareholders have been diluted in the past year (15% increase in shares outstanding). Market cap is less than US$100m (€52.7m market cap, or US$61.9m).
공지 • Oct 24Magis S.p.A. (BIT:MGS) announces an Equity Buyback for €0.8 million worth of its shares.Magis S.p.A. (BIT:MGS) announces an share repurchase program. Under the program, the company will repurchases up to €0.8 million. The program will valid till 18 months.
분석 기사 • Oct 16Why The 24% Return On Capital At Magis (BIT:MGS) Should Have Your AttentionIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. One common...
Major Estimate Revision • Oct 12Consensus EPS estimates fall by 28%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from €79.6m to €76.1m. EPS estimate also fell from €0.766 per share to €0.551 per share. Net income forecast to shrink 42% next year vs 17% decline forecast for Chemicals industry in Italy. Consensus price target down from €14.50 to €12.75. Share price fell 2.8% to €10.30 over the past week.
Price Target Changed • Oct 10Price target decreased by 15% to €12.75Down from €15.00, the current price target is an average from 2 analysts. New target price is 24% above last closing price of €10.30. Stock is down 21% over the past year. The company is forecast to post earnings per share of €1.63 for next year compared to €1.54 last year.
New Risk • Oct 01New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2024 fiscal period end). Earnings are forecast to decline by an average of 2.0% per year for the foreseeable future. Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (€62.3m market cap, or US$73.0m).
New Risk • Sep 29New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 2.5% per year for the foreseeable future. Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (€66.3m market cap, or US$77.6m).
Buy Or Sell Opportunity • Sep 24Now 20% overvaluedOver the last 90 days, the stock has fallen 16% to €11.40. The fair value is estimated to be €9.49, however this is not to be taken as a sell recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 1.5% per annum. Earnings are forecast to decline by 2.5% per annum over the same time period.
Buy Or Sell Opportunity • Sep 01Now 20% overvaluedOver the last 90 days, the stock has fallen 15% to €11.50. The fair value is estimated to be €9.56, however this is not to be taken as a sell recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 1.5% per annum. Earnings are forecast to decline by 2.5% per annum over the same time period.
Buy Or Sell Opportunity • Aug 13Now 20% overvaluedOver the last 90 days, the stock has fallen 13% to €11.50. The fair value is estimated to be €9.58, however this is not to be taken as a sell recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 1.5% per annum. Earnings are forecast to decline by 2.5% per annum over the same time period.
Major Estimate Revision • Aug 05Consensus EPS estimates fall by 39%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from €86.0m to €81.2m. EPS estimate also fell from €1.59 per share to €0.967 per share. Net income forecast to shrink 37% next year vs 6.0% decline forecast for Chemicals industry in Italy. Consensus price target down from €18.25 to €15.00. Share price fell 16% to €11.60 over the past week.
New Risk • Aug 04New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 2.5% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 2.5% per year for the foreseeable future. Minor Risks Share price has been volatile over the past 3 months (5.6% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (€65.7m market cap, or US$76.1m).
Valuation Update With 7 Day Price Move • Jul 31Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to €11.80, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 15x in the Chemicals industry in Italy. Negligible returns to shareholders over past year.
New Risk • Jun 12New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (€78.7m market cap, or US$91.3m).
New Risk • Jun 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Market cap is less than US$100m (€66.1m market cap, or US$75.3m).
New Risk • Apr 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (€69.1m market cap, or US$78.4m).
공지 • Apr 15Magis S.p.A., Annual General Meeting, Apr 28, 2025Magis S.p.A., Annual General Meeting, Apr 28, 2025, at 16:30 W. Europe Standard Time.
Buy Or Sell Opportunity • Apr 04Now 24% overvalued after recent price riseOver the last 90 days, the stock has risen 9.9% to €13.30. The fair value is estimated to be €10.75, however this is not to be taken as a sell recommendation but rather should be used as a guide only.
공지 • Apr 02Magis S.p.A. announces Annual dividend, payable on May 07, 2025Magis S.p.A. announced Annual dividend of EUR 0.9200 per share payable on May 07, 2025, ex-date on May 05, 2025 and record date on May 06, 2025.
분석 기사 • Mar 22We Think Magis (BIT:MGS) Might Have The DNA Of A Multi-BaggerIf you're looking for a multi-bagger, there's a few things to keep an eye out for. Amongst other things, we'll want to...
Buy Or Sell Opportunity • Mar 13Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 2.4% to €13.00. The fair value is estimated to be €10.57, however this is not to be taken as a sell recommendation but rather should be used as a guide only.
분석 기사 • Oct 04Magis (BIT:MGS) Strong Profits May Be Masking Some Underlying IssuesMagis S.p.A.'s ( BIT:MGS ) robust recent earnings didn't do much to move the stock. We think this is due to investors...
Reported Earnings • Sep 29First half 2024 earnings releasedFirst half 2024 results: Revenue: €43.8m (up 4.7% from 1H 2023). Net income: €4.52m (up 1.4% from 1H 2023). Profit margin: 10% (in line with 1H 2023). Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Chemicals industry in Italy.
New Risk • Sep 27New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (8.9% increase in shares outstanding). Market cap is less than US$100m (€63.5m market cap, or US$70.9m).
New Risk • Apr 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€51.5m market cap, or US$54.8m).
Reported Earnings • Sep 25First half 2023 earnings releasedFirst half 2023 results: Net income: €4.46m (up €4.46m from 1H 2022).